Drugs that boost the heart's IKs potassium channel to prevent long QT and dangerous arrhythmias
A full spectrum rational approach to identify antiarrhythmic agents targeting IKs Channels
This project looks for new medicines that strengthen a heart potassium channel (IKs) to shorten the heartbeat in people at risk of drug‑induced long QT and sudden arrhythmia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project ID | NIH-11349666 on NIH RePORTER |
What this research studies
The team uses a 'full spectrum rational' approach combining detailed channel structures and computer modeling to find compounds that promote IKs channel opening. They will map binding sites involved in calmodulin, ATP, PIP2, and pore opening and use that information to design candidate molecules. Promising compounds will be tested in cellular and preclinical models to see if they reverse drug‑induced action potential prolongation. If those tests succeed, the work could move toward safety testing and eventual human studies.
Who could benefit from this research
Good fit: People taking medications known to prolong the QT interval or those who have experienced drug‑induced QT prolongation or related arrhythmias would be the most relevant candidates for future trials.
Not a fit: Patients whose arrhythmias are caused by conditions unrelated to IKs channel dysfunction or by structural heart disease may not benefit from these agents.
Why it matters
Potential benefit: Could reduce drug‑induced long QT and lower the risk of life‑threatening arrhythmias, potentially allowing safer use of medications that currently cause QT problems.
How similar studies have performed: Laboratory and animal work has suggested that boosting IKs can shorten action potentials, but translating that into safe, effective drugs for people remains largely unproven.
Where this research is happening
Stony Brook, United States
- State University New York Stony Brook — Stony Brook, United States (Active)
Researchers
- Principal investigator: Lin, Richard Z — State University New York Stony Brook
- Study coordinator: Lin, Richard Z
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.